A1c: the version I wish someone had shown me in week 1
A1c: the version I wish someone had shown me in week 1. Numbers below. Ask me the boring questions, they are the useful ones.
A1c reflects average glycaemia over roughly the preceding three months, weighted towards the most recent weeks. It cannot show variability and it lags any change you make.
Postprandial excursions typically respond earlier than fasting glucose, so the sequence people observe is not a sign that something is not working.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Sensor accuracy varies across wear, and readings on the first day are the least reliable. Calibration practice and compression artefacts explain many alarming single values.
What does time in range look like, not just the average?
That A1c change is inside the assay’s variability and the interval you measured over is too short.
The diabetes and obesity programmes are separate, with different populations and different primary endpoints. Reading a result across from one to the other is not a comparison.
Time in range told me far more than the average did. Two quarters with the same A1c looked completely different on the sensor.
dose for glycaemic control is not the same conversation as dose for weight
Left up. It distinguishes the sensor data from the lab result, which most posts here do not.
That is a sensor value, not a plasma value, and the two are not interchangeable at that level of precision.
Yes — time in range tells you about variability, which the average deliberately hides.
Incretin-based agents stimulate insulin secretion in a glucose-dependent manner, which is why hypoglycaemia risk with them alone is low. Risk rises with agents that act independently of glycaemia.
This. Hypoglycaemia risk in this class is driven mostly by the other agents in the regimen.
variability matters as much as the mean
Incretin-based agents stimulate insulin secretion in a glucose-dependent manner, which is why hypoglycaemia risk with them alone is low.
This is the distinction that resolves most of the confusion here — average versus shape.
Brought the whole CGM export to my appointment rather than one number. Entirely different conversation.
The three numbers, and what each one can and cannot tell you.
A1c is an average over about three months, weighted to the recent weeks. It cannot show variability and it lags change. Continuous monitoring shows the shape — excursions, overnight, time in range — and is where improvement usually becomes visible first. Fingersticks are point measurements, useful for sanity-checking a sensor and for specific questions.
Most of the frustrated posts here come from expecting one of the three to answer a question that belongs to another. And all three are inputs to a conversation with whoever manages your care, which is not this board.
I would not compare your numbers to that population. Different baseline, different regimen, different trial.
Agreed. A1c is an integrated average over roughly three months and treating it as a current reading causes a lot of unnecessary alarm.
Cosigning that postprandial excursions improve first and the fasting number is the laggard.
What else is in the regimen?
- 1The diabetes and obesity programmes are separate, with different populations…6 comments in this branch · started by u/nhs_waitlist_n